GILD vs TBPH · P/E 18, rev $7.80B vs P/E 7.5, rev $38.4M
Gilead Sciences Inc (GILD) versus Theravance Biopharma Inc (TBPH) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported TBPH revenue for 2026-06-30 was $38.4M. Net income was -$10.8M. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Not investment advice. Open the GILD and TBPH stock pages for the full models.
Not investment advice.